709-1306

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2014-02-03

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-05-04 (study day 91.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE IRRITATION — outcome: RECOVERED/RESOLVED; onset 2014-05-04 (study day 91.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

mild assessed

Mild DRUG ERUPTION — outcome: RECOVERED/RESOLVED; onset 2014-05-20 (study day 107.0); relationship: NONE

mild assessed

Mild RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

moderate assessed

Moderate RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

moderate assessed

Moderate RASH — outcome: RECOVERED/RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

Data queries

No data queries.